ArthroCare Corp. (NASDAQ: ARTC), a leader in developing state-of-the-art, minimally invasive surgical products, announced its financial results for the fourth quarter and year ended December 31, 2012.
FOURTH QUARTER 2012 SUMMARY
FULL YEAR 2012 SUMMARY
REVENUE – FOURTH QUARTER
Total revenue for the fourth quarter of 2012 was $96.9 million, compared to $92.4 million for the fourth quarter of 2011, an increase of 4.9 percent.
Product sales for the fourth quarter of 2012 were $92.2 million compared to $88.5 million in the fourth quarter of 2011, an increase of 4.3 percent. Product sales increased 4.5 percent in constant currency over the same quarter of the prior year.
Worldwide sales of Sports Medicine products increased $1.2 million or 1.9 percent in the fourth quarter of 2012 when compared to the fourth quarter of 2011. In constant currency, Sports Medicine product sales increased 2.1 percent. In the fourth quarter of 2012 proprietary Sports Medicine product sales in the Americas increased $1.5 million, or 4.5 percent and International Sports Medicine product sales increased $1.9 million, or 9.5 percent as compared to the fourth quarter of 2011. Contract manufactured product sales decreased $2.2 million, or 28.0 percent in the fourth quarter.
Worldwide ENT product sales increased $2.5 million, or 10.6 percent in the fourth quarter of 2012 compared to the fourth quarter of 2011. Americas ENT product sales increased $0.8 million or 4.3 percent and International ENT product sales increased $1.7 million or 37.1 percent as a result of increased product sales in Asia Pacific markets, most notably in Australia and China in the fourth quarter.
Across all product areas International product sales increased $3.8 million, or 14.0 percent in the fourth quarter of 2012 as compared to the same quarter of 2011. Had the same foreign currency rates been in effect in the fourth quarter of 2012 as were in effect in the fourth quarter in 2011, the U.S. dollar reported value of product sales would have been higher by $0.2 million for the current quarter.
REVENUE – FULL YEAR
Total revenue from continuing operations in 2012 was $368.5 million, compared to $354.9 million for 2011.
Worldwide Sports Medicine product sales increased $7.4 million or 3.3 percent in 2012 compared to 2011 and increased 4.5 percent in constant currency. Sports Medicine product sales in the Americas increased $6.2 million in 2012 compared to 2011 as proprietary product sales increased $5.9 million or 4.6 percent in 2012. International Sports Medicine product sales increased $1.3 million or 1.6 percent in 2012 compared to 2011. Contract manufactured product sales increased $0.3 million, or 1.4 percent in 2012.
Worldwide ENT product sales increased $5.5 million or 5.5 percent in 2012 compared to 2011 and increased 6.0 percent in constant currency. ENT product sales in the Americas increased $1.1 million or 1.3 percent and International ENT product sales increased $4.4 million or 23.9 percent in 2012 compared to 2011.
Worldwide other product sales decreased $0.6 million in 2012 when compared to 2011 and represented less than 3 percent of total product sales in 2012.
Management believes percentage sales growth in constant currency is an important metric for evaluating our operations because the impact of changing foreign currency exchange rates may not provide an accurate baseline for analyzing trends in our business. Percentage sales growth in constant currency is calculated by translating current year sales at prior year average foreign currency exchange rates. Constant currency is a non-GAAP measure and it should not be considered as a substitute for measures prepared in accordance with GAAP.
INCOME FROM OPERATIONS – FOURTH QUARTER
Income from operations for the fourth quarter of 2012 was $15.1 million compared to a loss from operations of $51.4 million for the same period in 2011. The loss from operations for the fourth quarter of 2011 included a charge of $74.0 million for the settlement of securities class actions pending against the Company.
Gross product margin as a percentage of product sales was 69.9 percent for the fourth quarter of 2012 compared to 69.3 percent for the fourth quarter of 2011.
Total operating expenses were $54.1 million in the fourth quarter of 2012 compared to $116.7 million in the fourth quarter of 2011 as the fourth quarter of 2011 included a charge of $74.0 million for the settlement of securities class actions pending against the Company. The Company also incurred Exit costs of $3.0 million in the fourth quarter of 2011 in connection with the closure and relocation of its Sunnyvale, California operations that did not recur in 2012. Sales and marketing expenses increased $2.4 million, to 30.9 percent of total revenues this quarter compared to 29.8 percent for the same quarter of 2011.
INCOME FROM OPERATIONS – FULL YEAR
For the full year of 2012, income from operations was $64.1 million compared to a loss from operations in 2011 of $15.5 million. The 2011 loss from operations included $80.8 million for investigation and restatement expenses, mostly the result of the charge of $74.0 million for the settlement of the securities class actions pending against the Company in the fourth quarter of 2011.
Gross product margin as a percentage of product sales for the full year of 2012 was 69.2 percent compared to 69.5 percent in 2011.
Under the short-term incentive plan for 2012 approved by the Board of Directors, Adjusted Operating Margin is a key metric for purposes of evaluating business performance. Adjusted Operating Margin is Operating Margin adjusted for investigation and restatement related costs. Investigation and restatement related costs were 2.9 percent and 22.8 percent of total revenue for 2012 and 2011, respectively, and Adjusted Operating Margin was 20.3 percent and 18.4 percent, respectively, for these years. Adjusted Operating Margin is a non-GAAP measure of profitability and it should not be considered as a substitute for measures prepared in accordance with GAAP.
NET INCOME AVAILABLE TO COMMON STOCKHOLDERS
Net income applicable to common stockholders was $10.3 million or $0.30 per diluted share in the fourth quarter of 2012, compared to net loss attributable to common stockholders of $29.3 million, or a loss of $1.06 per share in the fourth quarter of 2011.
For the year ended December 31, 2012, net income applicable to common stockholders was $42.8 million, or $1.25 per diluted share, compared to net loss attributable to common stockholders of $4.3 million, or a loss of $0.16 per share for the year ended December 31, 2011.
BALANCE SHEET AND CASH FLOWS
Cash and cash equivalents was $218.8 million as of December 31, 2012 compared to $219.6 million at December 31, 2011. In the first quarter of 2012, the Company paid $74 million as required under the proposed settlement of the private securities class actions. Excluding this payment, cash and cash equivalents increased $73.2 million during the year ended December 31, 2012. Cash provided by operating activities for year ended December 31, 2012 was $6.3 million compared to cash provided by operating activities of $84.6 million for the year ended December 31, 2011. Adjusting for the funding of the $74 million settlement of the private securities class actions, cash provided by operating activities in 2012 was $80.3 million.
ArthroCare will hold a conference call with the financial community to present these results at 8:30 a.m. ET/5:30 a.m. PT on Thursday, February 14, 2013. To participate in the live conference call dial 800-763-5654. A live and on-demand webcast of the call will be available on ArthroCare’s Web site at www.arthrocare.com. A telephonic replay of the conference call can be accessed by dialing 800-633-8284 and entering pass code number 21648357. The replay will remain available through February 28, 2013.
ArthroCare develops and manufactures surgical devices, instruments, and implants that strive to enhance surgical techniques as well as improve patient outcomes. Its devices improve many existing surgical procedures and enable new minimally invasive procedures. Many of ArthroCare’s devices use its internationally patented Coblation® technology. This technology precisely dissolves target tissue and limits damage to surrounding healthy tissue. ArthroCare also develops surgical devices utilizing other patented technology including its OPUS® line of fixation products as well as re-usable surgical instruments. ArthroCare is leveraging these technologies in order to offer a comprehensive line of surgical devices to capitalize on a multi-billion dollar market opportunity across several surgical specialties, including its two core product areas consisting of Sports Medicine and Ear, Nose, and Throat as well as other areas such as spine, wound care, urology and gynecology.
The information provided herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on beliefs and assumptions by management and on information currently available to management. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Additional factors that could cause actual results to differ materially from those contained in any forward-looking statement include, without limitation: the resolution of litigation pending against the Company; the impact upon the Company’s operations of legal compliance matters which may require improvement and remediation; the ability of the Company to control expenses relating to legal or compliance matters; the Company’s ability to remain current in its periodic reporting requirements under the Exchange Act and to file required reports with the Securities and Exchange Commission on a timely basis; the results of the investigation being conducted by the United States Department of Justice; the impact on the Company of additional civil and criminal investigations by state and federal agencies and civil suits by private third parties involving the Company’s financial reporting and its previously announced restatement and its insurance billing and healthcare fraud-and-abuse compliance practices; the results of the civil investigation by the Department of Justice related to the Civil Investigative Demand we received arising under the False Claims Act; the possibility that the Department of Justice could institute civil proceedings against us, based on the results of the investigation related to the Civil Investigative Demand; the risk that we could be subject to qui tam suits involving the False Claims Act; the possibility that the Department of Justice could institute a criminal enforcement action against us based on the results of the civil investigation related to the Civil Investigative Demand; the resolution of any litigation related to the civil investigation; the ability of the Company to attract and retain qualified senior management and to prepare and implement appropriate succession planning for its Chief Executive Officer; general business, economic and political conditions; competitive developments in the medical devices market; changes in applicable legislative or regulatory requirements; the Company’s ability to effectively and successfully implement its business strategies, and manage the risks in its business; and the reactions of the marketplace to the foregoing.
|Condensed Consolidated Balance Sheets - Unaudited|
|(in thousands, except par value data)|
|Cash and cash equivalents||$||218,787||$||219,605|
|Accounts receivable, net of allowances of $1,565 and $2,251 at 2012 and 2011, respectively||48,881||51,350|
|Deferred tax assets||20,090||40,622|
|Prepaid expenses and other current assets||6,022||5,532|
|Total current assets||342,197||352,870|
|Property and equipment, net||30,461||35,769|
|Intangible assets, net||1,859||5,457|
|Deferred tax assets||23,206||18,159|
|LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY|
|Deferred tax liabilities||33|
|Income tax payable||286||1,542|
|Total current liabilities||54,467||130,128|
|Deferred tax liabilities||354||29|
|Other non-current liabilities||20,200||18,922|
|Commitments and contingencies (Notes 9 and 10)|
|Series A 3% Redeemable Convertible Preferred Stock, par value $0.001; Authorized: 100 shares;|
|Issued and outstanding: 75 shares at December 31, 2012 and December 31, 2011; Redemption|
|Preferred stock, par value $0.001; Authorized: 4,900 shares; Issued and outstanding: none|
|Common stock, par value $0.001; Authorized: 75,000 shares; Issued: 31,949 and 31,523;|
Outstanding: 27,977 and 27,562 shares at December 31, 2012 and 2011, respectively
|Treasury stock: 3,942 and 3,968 shares at December 31, 2012 and 2011, respectively||(106,425||)||(107,126||)|
|Additional paid-in capital||413,660||400,580|
Accumulated other comprehensive income
|Total stockholders' equity||364,007||306,738|
|Total liabilities, redeemable convertible preferred stock and stockholders' equity||$||519,787||$||533,001|
Condensed Consolidated Statements of Comprehensive Income - Unaudited
|(in thousands, except per share data)|
|Three Months Ended||Year Ended|
|December 31,||December 31,|
|Royalties, fees and other||4,713||3,957||17,783||16,566|
|Cost of product sales||27,741||27,144||107,951||103,314|
|Research and development||8,469||7,472||32,146||28,932|
|Sales and marketing||29,910||27,497||116,127||108,621|
|General and administrative||8,379||8,697||33,212||35,069|
|Amortization of intangible assets||857||1,319||4,857||5,291|
|Investigation and restatement-related costs||6,442||68,680||10,805||80,825|
|Total operating expenses||54,057||116,661||196,369||267,038|
Income (loss) from operations
|Interest and other income (expense), net||151||(670||)||(427||)||(1,331||)|
Income (loss) from continuing operations before income taxes
Income tax provision (benefit)
Net income (loss) from continuing operations
|Income from discontinued operations, net of taxes||-||-||-||1,911|
Net income (loss)
Accrued dividend and accretion charges on Series A
|3% Redeemable Convertible Preferred Stock||(909||)||(870||)||(3,575||)||(3,416||)|
Net income (loss) available to common stockholders
|Other comprehensive income|
|Foreign currency translation adjustments||120|
Total comprehensive income (loss)
Weighted average shares outstanding:
Earnings (loss) per share from continuing operations
|applicable to common stockholders:|
Earnings (loss) per share applicable to common stockholders:
|Supplemental Schedule of Product Sales - Unaudited|
|Three Months Ended||Three Months Ended|
|December 31, 2012||December 31, 2011|
|Total product sales||$||61,701||$||30,522||$||92,223||100.0||%||$|
|Year Ended||Year Ended|
|December 31, 2012||December 31, 2011|
|Total product sales||$||239,875||$||110,796||$||350,671||100.0||%||$||233,605||$||104,714||$||338,319||100.0||%|
Reconciliation of Income from Operations to Adjusted Income from Operations - unaudited
|Quarter ended December 31,||Year ended December 31,|
|Income from operations||$||15,138||$||(51,393||)||$||64,134||$||(15,467||)|
|Investigation and restatement-related costs||6,442||68,680||10,805||80,825|
|Non-GAAP adjusted income from operations||21,580||17,287||74,939||65,358|
|Non-GAAP Adjusted Operating Margin||22.3||%||18.7||%||20.3||%||18.4||%|